Dr. Rosenberg on the KEYNOTE-045 Trial in Advanced Urothelial Cancer

In Partnership With:

Jonathan E. Rosenberg, MD, discusses the phase 3 KEYNOTE-045 trial in advanced urothelial cancer.

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the phase 3 KEYNOTE-045 trial in advanced urothelial cancer.

KEYNOTE-045 randomized patients with advanced urothelial cancer who had progressed or recurred on platinum-based chemotherapy to pembrolizumab (Keytruda) or investigator’s choice of paclitaxel, docetaxel, or vinflunine.

Results showed that patients who received pembrolizumab had prolonged overall survival compared with those who received chemotherapy. Moreover, long-term follow-up results revealed that 20.7% of patients who responded to pembrolizumab experienced durable responses lasting 3 years, says Rosenberg.

Advanced urothelial cancer is associated with a 5% to 10% survival rate, says Rosenberg. Using a single-agent checkpoint inhibitor in the second-line setting could improve survival for these patients.

KEYNOTE-045 revealed that patients with a PD-L1 combined positive score (CPS) of 10% or greater did not derive a significant improvement in outcomes compared with the total population, says Rosenberg. As such, PD-L1 testing is not done for patients who progress on prior platinum chemotherapy.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Related Content